Oncobiologics names Canute to board of directors

Wednesday, October 12, 2011 11:31 AM

Oncobiologics has named Scott Canute to its board of directors.

Over the course of his 30-year career, Canute played a vital role in leading Eli Lilly's global manufacturing operations.  Most recently, he spent more than a year as president of global manufacturing and corporate operations for Genzyme.

"Scott Canute has been a distinguished leader at major biopharmaceutical organizations throughout his career," said Oncobiologics founder & CEO Pankaj Mohan, Ph.D.  "I have known and admired Scott as my mentor for many years, and I am honored that he will share his experience and strategic insight to our efforts at Oncobiologics.  We look forward to guidance from Scott as a member of our board."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs